Government, industry, and advocacy together will provide nearly $130 million for the identification of surrogate markers and targets.
Allegations of falsified data embroil Japanese ADNI; project leaders respond that data corrections followed quality-control procedures.
A combination of high clusterin and low Aβ42 in cerebrospinal fluid associates with early Alzheimer’s neurodegeneration, hinting at a mechanistic interaction between the proteins.
Evidence builds that amyotrophic lateral sclerosis and frontotemporal lobar degeneration sit on the same pathological spectrum, but scientists are unsure how the disease marker TDP-43 fits in.
A small panel of fluid biomarkers could predict a slow or fast disease course in amyotrophic lateral sclerosis.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
People with neurodegeneration but not brain amyloid surface in two new studies of preclinical AD, suggesting this odd population is both legitimate and potentially large.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
Among cognitively healthy older adults, the rate of change in cerebrospinal fluid biomarkers helps predict who will develop Alzheimer’s disease.
People who carry the Huntington’s gene develop progressively abnormal brain metabolism a decade or more before diagnosis.
Interested in Parkinson's? Apply for access to data and tissue samples, and funds to study them, from the Michael J. Fox Foundation.
Proposed preclinical stages for Alzheimer’s disease predict well who is most likely to progress to Alzheimer’s dementia.
The first report on PBB3, the latest tau ligand for brain imaging under development, suggests it binds all types of tau aggregate.
A new study supports the idea that non-motor symptoms of Parkinson's disease may aid earlier diagnosis.
Researchers nabbed rare variants in Alzheimer’s genes by sequencing DNA from people with very high or very low levels of cerebrospinal fluid biomarkers.